Agreement follows positive phase III data announcement
News
NICE green light for Cablivi in rare blood-clotting disorder
Treatment recommended for acquired thrombotic thrombocytopenic purpura
Russian says its ‘Sputnik V’ COVID-19 vaccine is 92% effective
Interim data analysis comes from phase III clinical trials in the Russian Federation
Pfizer’s abrocitinib scores another phase III win in atopic dermatitis
JADE REGIMEN study investigated JAK1 inhibitor in moderate to severe atopic dermatitis
Mallinckrodt launches retrospective study for inhaled therapy in COVID-19
Study will collect real-world data on use of INOmax in COVID-19 patients
UCB acquires gene therapy specialist Handl Therapeutics
Company also announces new collaboration with Lacerta Therapeutics
ViiV’s long-acting HIV drug beats standard of care in prevention study
Study was ended early after drug hit primary endpoint
AbbVie’s Venclyxto gets NICE blood cancer backing
Oral B-cell lymphoma-2 inhibitor approved to treat chronic lymphocytic leukaemia
Amgen, AZ’s asthma drug tezepelumab scores phase III win
Detailed results are due to be presented at forthcoming medical meeting
FDA grants emergency authorisation to Lilly’s COVID-19 antibody
Bamlanivimab approved for high-risk COVID-19 patients
UK study will evaluate aspirin as a potential COVID-19 treatment
RECOVERY study will assess if drug can reduce risk of blood clots
EU OK for AZ’s Calquence in CLL
BTK inhibitor approved based on results from two phase III trials
Waylivra, Tecentriq and more accepted by SMC
Akcea’s Waylivra approved via ultra-orphan pathway
New NHS Digital deal set to improve data sharing between different organisations
Deal will help to support integrated health and care activities
BREAKING NEWS: early data indicates Pfizer/BioNTech’s COVID-19 vaccine is 90% effective
Phase III study of vaccine candidate involved 43,538 participants
